Outset Halts Tablo Sales for Home Use Pending FDA Review of New Features
As Outset has added features improving Tablo since the FDA first cleared it for use, it has now had to submit another 510(k) application to the FDA, thus limiting sales to acute facilities only.
Read the full article » | Posted 07-13-2022
Related Articles
- CMS Relocates ESRD Survey Procedures and Interpretive Guidance Posted 06-17-2026
- CMS announced new 5-year contracts for ESRD Networks, which started May 1 Posted 06-17-2026
- Simon Davies Discusses the Role of PD in Expanding Dialysis Acess Posted 05-15-2026
- Less Home Dialysis and Transplant in Pediatric Patients Transitioning to Adult Clinics Posted 05-15-2026

